Oct 26 (Reuters) - A U.S. court on Monday allowed Eli Lilly to continue weight-loss drug advertisements that rival Novo Nordisk claimed were false and misleading.
(Reporting by Jonathan Stempel in New York)
US judge lets Eli Lilly continue ads for weight-loss drugs, rules against Novo Nordisk
